CoreValve announces that more than 500 high-risk patients have been treated with its ReValving(R) System for percutaneous aortic valve replacement (PAVR): Company's 18-French ReValving(R) System, which received European regulatory clearance in mid-2007, is the smallest PAVR system in the clinic

Share Article

CoreValve (http://www.corevalve.com) announced today that the expanded clinical evaluation of its ReValving(R) System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis is enrolling patients at 32 sites in 11 European countries. The ReValving(R) System procedures can be performed under local anesthesia, without the need for surgical cut-down/repair, and without hemodynamic support or artificially accelerating the heart rate.

    Clinical results to date not only underscore the acute procedural benefits of PAVR for high-risk and inoperable patients, but also demonstrate the potential for reduced hospital stays and for high quality-of-life patient outcomes. The ReValving(R) System bioprosthesis, which was specifically designed for transcatheter delivery, now has positive follow-ups out to nearly three years in this octogenarian patient population.

About CoreValve

CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving(R) System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving(R) System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at http://www.corevalve.com.

(Caution: the CoreValve ReValving(R) System will not be available in the USA for clinical trials or for sale until further notice.)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald Trahan
Visit website